Wegovy has a multiyear head start on trial data. Tirzepatide now has the supporting data but it takes a long time for official approval… it’s coming.
Most believe Reta will do the same, and early data supports, but it has a much longer road to non weight loss related approval. There is also concern the increased heart rate risk, which occurs with Wegovy but less severe, might disqualify heart patients.
@pwillie67@drmikehart Tirzepatide shows a similar non weight related MACE reduction as Wegovy. It just hasn’t been approved for it yet. Probably next year.
@chriswithans My daughter voted in the last election. This time they sent her a letter saying her signature didn’t match. So… she has to fill out, sign, and mail another document. I wonder how many people wouldn’t go through the “hassle.”